Applying Artificial Intelligence to Optimize Early-stage Hepatocellular Carcinoma Treatment Based on Multi-modal Image

Hepatocellular Carcinoma Clinical Trial

— AI-HCC  

Official title:

Artificial Intelligence to Optimize Early-stage Hepatocellular CarcinomaTreatment Based on Multi-modal Image

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05627297
• Other study ID #: WentaoKong
• Status: Recruiting
• Start date: December 1, 2022
• Est. completion date: November 1, 2025

Study information

• Verified date: November 2022
• Source: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
• Contact: Wentao Kong
• Phone: 13815897824
• Email: breezewen[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study intends to establish two prognostic models based on contrast-enhanced ultrasound (CEUS) and dynamic enhanced magnetic resonance (DE-MRI) multimodal images: prognostic model of liver cancer patients after hepatectomy and prognostic model of liver cancer patients after radiofrequency ablation. Combined with artificial intelligence imaging omics, traditional imaging omics and clinical information, to predict and compare the prognosis of two different treatment methods for early liver cancer, so as to realize the individual selection of treatment methods for early liver cancer patients

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: November 1, 2025
• Est. primary completion date: November 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Primary single hepatocellular carcinoma confirmed by histology or cytology, with a maximum diameter =5.0 cm;

• Good liver function, Child-Pugh grade A;

• No serious dysfunction of heart, lung, kidney and other important organs ? Liver resection or radiofrequency ablation was performed in our hospital, and the study protocol and follow-up procedure were followed.

Exclusion Criteria:

• Patients who cannot perform DCE-MRI examination due to metal implants in the body ? Patients who had received other treatment before DCE-MRI or CEUS;

• Invisible lesions, diffuse lesions or poor DCE-MRI/CEUS image quality under CEUS; ? Drug abuse, clinical or psychological or social factors that make informed consent or study implementation affected.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Other:
• CEUS and CEMRI
contrast-enhanced ultrasound and contrast-enhanced MRI examination

Locations

Country	Name	City	State
China	Nanjing Drum Tower Hospital	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Good/Poor overall survival		2022/12/01-2025/12/01